Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: A placebo-controlled, triple-blind, randomized trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210915052492N1

Enrollment

Registered

2021-10-11

Start date

2020-03-01

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant pleural effusion. Malignant pleural effusion

Interventions

Intervention 1: Intervention group: Patients in the octreotide group received 50-microgram subcutaneous injections of octreotide acetate (Novartis, Switzerland) three times/day for up to 5 days prior

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with cancer and malignant pleural effusion Chest tube discharge>150 cc/day Estimated survival>6 months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The amount of discharge from the chest tube before and after pleurodesis. Timepoint: Before and after intervention. Method of measurement: Chest tube.	—

Secondary

Measure	Time frame
Hospital stay. Timepoint: After intervention. Method of measurement: Days.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMatin Vahedi

Tehran University of Medical Sciences

dr.matinvahedi@gmail.com+98 21 2221 4676

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026